Svb Leerink Comments on Sientra Inc’s FY2021 Earnings (SIEN)

Share on StockTwits

Sientra Inc (NASDAQ:SIEN) – Research analysts at Svb Leerink issued their FY2021 earnings estimates for shares of Sientra in a research report issued on Wednesday, March 13th. Svb Leerink analyst R. Newitter anticipates that the medical instruments supplier will post earnings of ($1.38) per share for the year.

A number of other analysts have also weighed in on the stock. Wells Fargo & Co initiated coverage on shares of Sientra in a report on Thursday. They issued a “market perform” rating and a $9.00 price target for the company. ValuEngine cut shares of Sientra from a “buy” rating to a “hold” rating in a research report on Thursday. Stifel Nicolaus reduced their price target on shares of Sientra from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. Dougherty & Co cut their price objective on shares of Sientra from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Leerink Swann lowered their price target on shares of Sientra from $22.00 to $18.00 in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $19.50.

NASDAQ SIEN opened at $8.34 on Thursday. The company has a market cap of $325.46 million, a PE ratio of -2.57 and a beta of -0.04. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.77 and a quick ratio of 2.34. Sientra has a 1-year low of $7.74 and a 1-year high of $26.79.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.19). The business had revenue of $19.02 million for the quarter, compared to the consensus estimate of $18.87 million. Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Sientra in the fourth quarter valued at $29,000. Great West Life Assurance Co. Can bought a new position in shares of Sientra during the fourth quarter valued at about $64,000. Metropolitan Life Insurance Co. NY lifted its position in shares of Sientra by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 6,397 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Sientra during the fourth quarter worth about $135,000. Finally, HRT Financial LLC purchased a new stake in Sientra during the fourth quarter worth about $157,000. 92.79% of the stock is currently owned by institutional investors and hedge funds.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Story: What is Call Option Volume?

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Financial Review: SGS  & Its Rivals
Financial Review: SGS & Its Rivals
National Access Cannabis  and Humana  Critical Analysis
National Access Cannabis and Humana Critical Analysis
SThree  Stock Rating Reaffirmed by UBS Group
SThree Stock Rating Reaffirmed by UBS Group
Legal & General Group  Stock Rating Upgraded by JPMorgan Chase & Co.
Legal & General Group Stock Rating Upgraded by JPMorgan Chase & Co.
LEG & GEN GRP P/S  Stock Rating Upgraded by JPMorgan Chase & Co.
LEG & GEN GRP P/S Stock Rating Upgraded by JPMorgan Chase & Co.
DZ Bank Reaffirms Neutral Rating for Leoni
DZ Bank Reaffirms Neutral Rating for Leoni


© 2006-2019 Ticker Report